Loading…
Harvard Bioscience Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -89.4% over 5Y.
today you would have $114.04▼ -88.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $6.70 | $21.10 | $53.50 | $27.70 | $70.50 | $42.90 | $30.50 | $31.80 | $33.00 | $30.50 | $34.70 | $56.70 | $47.00 | $33.21 | $29.34 | $30.93 | $27.07 | |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BDMDBaird Medical Investment Holdings Ltd | $1.12 | — | 0.7x | — | -77.60% | $35.82M |
| CNTXContext Therapeutics Inc. | $0.38 | — | 0.9x | — | -76.14% | $35.25M |
| ATYRaTYR PHARMA INC | $0.36 | — | 0.7x | — | -98.68% | $34.96M |
| COSMCosmos Health Inc. | $0.37 |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Company description provided by Yahoo Finance.
| P/E |
| 22.6x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 81.0x |
| — |
| 41.5x |
| 22.6x |
| 6.3x |
| 14.9x |
| P/S | 1.1x | 0.3x | 1.0x | 2.1x | 1.0x | 2.4x | 1.7x | 1.0x | 1.0x | 1.5x | 1.0x | 1.1x | 1.7x | 1.4x | 1.2x | 1.0x | 1.1x | 1.2x |
| P/B | 1.5x | 2.2x | 1.5x | 3.2x | 1.6x | 3.5x | 2.2x | 1.4x | 1.4x | 1.5x | 1.5x | 1.5x | 2.0x | 1.6x | 1.3x | 1.2x | 1.3x | 1.4x |
| EPS | -$12.80 | -$2.80 | -$0.80 | -$2.30 | -$0.10 | -$2.00 | -$1.20 | -$0.80 | -$0.20 | -$1.30 | -$5.70 | $0.70 | -$0.60 | $0.80 | $1.30 | $4.93 | $1.82 |
| Profit margin | -2.42% | -65.51% | -13.18% | -3.04% | -8.40% | -0.24% | -7.65% | -4.03% | -2.42% | -1.12% | -4.12% | -17.52% | 2.17% | -1.74% | 2.13% | 3.50% | 17.58% | 8.43% |
| ROE | -3.53% | -412.84% | -19.58% | -4.67% | -13.18% | -0.35% | -10.19% | -5.74% | -3.53% | -1.07% | -5.97% | -24.54% | 2.47% | -1.94% | 2.27% | 3.99% | 21.07% | 9.61% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
1 methods answered, across 1 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+76.3% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| — |
| 1.4x |
| — |
| -104.00% |
| $37.25M |
| RADXRadiopharm Theranostics Ltd | $2.41 | — | 0.8x | — | -92.10% | $34.84M |
| ONMDOneMedNet Corp | $0.63 | — | — | — | — | $37.53M |